INCYTE CORPORATION

NASDAQ: INCY (Incyte Corporation)

最近更新时间: 2天之前, 12:11PM

78.39

0.19 (0.24%)

前收盘价格 78.20
收盘价格 78.24
成交量 1,115,548
平均成交量 (3个月) 1,840,143
市值 15,307,685,888
市盈率 (P/E TTM) 18.53
预期市盈率 (P/E Forward) 13.14
价格/销量 (P/S) 3.28
股市价格/股市净资产 (P/B) 3.54
52周波幅
53.56 (-31%) — 83.95 (7%)
利润日期 28 Oct 2025
营业毛利率 0.48%
营业利益率 (TTM) 20.65%
稀释每股收益 (EPS TTM) 0.200
季度收入增长率 (YOY) 19.50%
季度盈利增长率 (YOY) -6.70%
总债务/股东权益 (D/E MRQ) 1.18%
流动比率 (MRQ) 2.04
营业现金流 (OCF TTM) 382.59 M
杠杆自由现金流 (LFCF TTM) 618.05 M
资产报酬率 (ROA TTM) 2.04%
股东权益报酬率 (ROE TTM) 0.47%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看跌
Biotechnology (全球的) 混合的 看跌
股票 Incyte Corporation 看涨 看涨

AIStockmoo 评分

0.5
分析师共识 1.5
内部交易活动 NA
价格波动 -3.5
技术平均移动指标 0.0
技术振荡指标 4.0
平均 0.50

相关股票

股票 市值 DY P/E(TTM) P/B
INCY 15 B - 18.53 3.54
ALNY 58 B - - 219.46
ROIV 8 B - - 1.70
MRUS 5 B - - 5.89
WVE 1 B - - 9.11
REGN 59 B 0.31% 13.98 2.02

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

部门 Healthcare
行业 Biotechnology
投资方式 Mid Core
内部持股比例 2.01%
机构持股比例 100.65%
52周波幅
53.56 (-31%) — 83.95 (7%)
目标价格波幅
60.00 (-23%) — 107.00 (36%)
107.00 (Stifel, 36.50%) 购买
79.00 (0.78%)
60.00 (BMO Capital, -23.46%) 卖出
平均值 81.67 (4.18%)
总计 4 购买, 4 保留, 1 卖出
平均价格@调整类型 75.80
公司 日期 目标价格 调整类型 价格@调整类型
Wells Fargo 06 Aug 2025 89.00 (13.53%) 购买 77.65
30 Jul 2025 67.00 (-14.53%) 保留 77.55
Barclays 01 Aug 2025 90.00 (14.81%) 购买 75.59
BMO Capital 30 Jul 2025 60.00 (-23.46%) 卖出 77.55
Citigroup 30 Jul 2025 103.00 (31.39%) 购买 77.55
RBC Capital 30 Jul 2025 72.00 (-8.15%) 保留 77.55
Truist Securities 30 Jul 2025 79.00 (0.78%) 保留 77.55
27 May 2025 73.00 (-6.88%) 保留 65.35
UBS 30 Jul 2025 68.00 (-13.25%) 保留 77.55
03 Jun 2025 61.00 (-22.18%) 保留 67.11
JP Morgan 14 Jul 2025 67.00 (-14.53%) 保留 69.98
Stifel 16 Jun 2025 107.00 (36.50%) 购买 71.22
显示更多

该时间范围内无数据。

日期 类型 细节
04 Aug 2025 公告 Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
31 Jul 2025 公告 Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil
29 Jul 2025 公告 Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
24 Jul 2025 公告 Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
10 Jul 2025 公告 Incyte to Report Second Quarter Financial Results
02 Jul 2025 公告 Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26 Jun 2025 公告 Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
20 Jun 2025 公告 Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
18 Jun 2025 公告 Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
15 Jun 2025 公告 QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
15 Jun 2025 公告 Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
12 Jun 2025 公告 Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
12 Jun 2025 公告 Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
06 Jun 2025 公告 Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Jun 2025 公告 Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
15 May 2025 公告 Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票